Paroxetine: safety and tolerability issues
| Autor: | Ashwin A. Patkar, Chi-Un Pae, David M. Marks, Byung Joo Ham, Min Hyeon Park, Prakash S. Masand, Changsu Han |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
medicine.medical_specialty Adolescent behavioral disciplines and activities Pregnancy Internal medicine mental disorders medicine Adverse Drug Reaction Reporting Systems Humans Drug Interactions Pharmacology (medical) Child Psychiatry Aged Clinical Trials as Topic business.industry Mental Disorders Panic disorder Social anxiety General Medicine medicine.disease Paroxetine Discontinuation Sexual dysfunction Tolerability Delayed-Action Preparations Major depressive disorder Female medicine.symptom business Premenstrual dysphoric disorder Selective Serotonin Reuptake Inhibitors medicine.drug |
| Zdroj: | Expert Opinion on Drug Safety. 7:783-794 |
| ISSN: | 1744-764X 1474-0338 |
| DOI: | 10.1517/14740330802423168 |
| Popis: | Paroxetine is a selective serotonin re-uptake inhibitor (SSRI) available in immediate release and controlled release (CR) formulations. Paroxetine is the most potent inhibitor of serotonin re-uptake among the now available SSRIs. Paroxetine has been approved for the treatment of major depressive disorder (MDD), obsessive-compulsive disorder, panic disorder (PD), generalised anxiety disorder, post traumatic stress disorder (PTSD), and social anxiety disorder (SAD) in adults, whereas paroxetine CR is approved for the treatment of MDD, SAD, PD and premenstrual dysphoric disorder in adults. The overall efficacy of paroxetine seems to be comparable to other SSRIs in the treatment of approved indications, although paroxetine treatment induces more sedation, constipation, sexual dysfunction, discontinuation syndrome and weight gain than other SSRIs. Recent data suggest that paroxetine treatment leads to increased rates of congenital malformations, although this evidence is not conclusive. Paroxetine and paroxetine CR are not indicated for use in the paediatric population and are categorised as Pregnancy Class D. In conclusion, whether the tolerability profile of paroxetine differs substantially from other new antidepressants (including other SSRIs) needs to be determined in adequately powered well-designed randomised controlled comparative clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|